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H I G H L I G H T S
• Ecstasy users differ from non-users on several characteristics.• Ecstasy use often precedes first use of other illicit substances.• Ecstasy use (or related environmental factors) may increase risk of substance use.
A B S T R A C T
Objective: Ecstasy is one of the most commonly used illicit substances in Western countries. The aim of this study is to identify characteristics of ecstasy users in a
large population-based sample of adults aged 18–45 years.
Method: With generalized estimating equation models we explored the association between self-reported lifetime ecstasy use and urbanicity, educational attainment,
health, wellbeing, stress, other substance use, personality traits and psychopathology in a Dutch twin sample (N = 9578, 66.8% female, 18–45 years). We also
explored the nature of the association (underlying genetic factors, shared environmental factors or a causal relationship) with the co-twin control method.
Results: Lifetime ecstasy users (N = 945, 9.9%) were more often male, younger, living more often in urban areas, higher educated, less satisfied with life and more
stressed than non-users. Ecstasy users scored differently on most personality and psychopathology scales compared to non-users and were more likely to have used
every other substance we investigated. Whereas smoking tobacco and alcohol use often preceded first use of ecstasy, first ecstasy use often preceded first use of other
illicit substances. A combination of scenarios (both causal and environmental/genetic) explained the strong associations between ecstasy and substance use.
Conclusions: Ecstasy users differ on many characteristics from non-users, and especially on illicit substance use. Our results indicate that causal effects may play a role
in explaining the relationship between ecstasy use and other illicit substance use.
1. Introduction
One of the most popular illicit substances is ecstasy, or MDMA (3,4-
methylenedioxymethamphetamine), with an annual prevalence of
around 19 million users worldwide in 2014 (United-Nations-Office-on-
Drugs-and-Crime, 2016). In Europe, approximately 1.7% of young
adults (15–34 years) has taken ecstasy in 2014, with estimates ranging
from 0.3% to 5.5% between countries (EMCDDA, 2016). Ecstasy is a
recreational drug, popular in Western Europe and the United States; the
prevalence of lifetime ecstasy use has been estimated to be ~11.3% in
12–34 year olds in the US (Palamar, Martins, Su, & Ompad, 2015), and
~13.0% in 15–34 year olds in the Netherlands (van Laar et al., 2016).
Desired effects of ecstasy include an enhanced sense of well-being,
emotional warmth, empathy, sensory motor perception and increased
extraversion and a willingness to discuss emotionally-charged mem-
ories (NIDA, 2017). However, (occasional as well as regular) ecstasy use
can also induce acute negative health effects such as hyperthermia,
hypertension, elevated heart rate and hyponatraemia (Gowing, Henry-
Edwards, Irvine, & Ali, 2002; de la Torre et al., 2000) and in some cases,
ecstasy use can lead to death (Milroy, 2011). As ecstasy is still a popular
drug of choice amongst young adults and is associated with some ad-
verse health effects and intoxications, it is important to understand
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characteristics of ecstasy users in order to improve prevention.
Several studies have examined characteristics of ecstasy users be-
fore. What was found in these studies is that ecstasy is primarily taken
by young adults, and more often by males than females (Degenhardt,
Barker, & Topp, 2004; van Laar et al., 2016; von Sydow, Lieb, Pfister,
Höfler, & Wittchen, 2002). In addition, users more often live in urba-
nized areas compared to non-users (Lai et al., 2016; van Laar et al.,
2016). In a Dutch study, ecstasy was more often taken by higher edu-
cated than lower educated individuals (van Laar et al., 2016), but this
was not true in an Australian study based on a household survey
(Degenhardt et al., 2004). Recent ecstasy users are more likely to have
used a range of other substances than non-ecstasy users (Smith, Farrell,
Bunting, Houston, & Shevlin, 2011; Bobes et al., 2002; Degenhardt
et al., 2004; Singer, Linares, Ntiri, Henry, & Minnes, 2004; Strote, Lee,
& Wechsler, 2002). In addition, differences on personality character-
istics have been observed; in particular, higher impulsivity, more sen-
sation seeking, higher scores on extraversion, and higher levels of
neuroticism and psychoticism are found in ecstasy users compared to
non-users or non-ecstasy users (Bobes et al., 2002; Butler &
Montgomery, 2004; ter Bogt, Engels, & Dubas, 2006; Singer et al.,
2004). Several studies indicate that ecstasy users show more symptoms
of psychopathology too, in particular depression and anxiety symptoms,
compared with non-users (Guillot, 2007; Morgan, 2000). Whereas some
studies reported that these symptoms already existed (long) before the
use of ecstasy (e.g. (Huizink, Ferdinand, van der Ende, & Verhulst,
2006)), others suggested that ecstasy use may cause long-term psy-
chopathology (Taurah, Chandler, & Sanders, 2014; Montoya,
Sorrentino, Lukas, & Price, 2002). Studies investigating the relationship
between ecstasy use and psychopathology other than depressive or
anxiety symptoms, such as attention problems or antisocial behaviour,
are scarce (Huizink et al., 2006).
Although characteristics of ecstasy users have been investigated in
previous studies, many of these studies recruit people through targeted
sampling, for example through advertising at dance parties, night clubs
and raves (Degenhardt et al., 2004). The extent to which such specific
samples are representative of ecstasy users in general is not clear.
Moreover, many of these studies were based on small sample sizes and
focus on a limited number of characteristics. Last, none of these studies
corrected for (early) home environment and genetic factors when in-
vestigating the relationship between ecstasy use and other character-
istics.
The aim of the present study is to identify characteristics of ecstasy
users in a large (N = 9578) population-based sample of adults aged
18–45 years. First, we compare individuals who have used ecstasy
during their lifetime (ecstasy users) with individuals who have never
used ecstasy (non-users) on variables in the categories (1) demo-
graphics, health, wellbeing and stress, (2) substance use (licit and il-
licit), (3) personality traits and (4) symptoms of psychopathology.
Subsequently, we investigate the order of substance use (age at initia-
tion). Last, we aim to provide insight into the nature of the associations
(causal, environmental, genetic) between ecstasy use and the variables
described above using the co-twin control method.
2. Materials and methods
2.1. Study design and participants
Data were collected in the 10th survey (2013–2014) of a long-
itudinal study in Dutch twins and their family members register at The
Netherlands Twin Register (Treur, Boomsma, Ligthart, Willemsen, &
Vink, 2016; Willemsen et al., 2013). The study was approved by the
medical ethical committee of the VU medical centre, Amsterdam, the
Netherlands. In total, 19,699 individuals completed survey 10. We in-
cluded participants who provided information on lifetime ecstasy use
and were aged between 18 and 45 years because of the very low pre-
valence of ecstasy use (1.0%) among individuals older than 45 years.
This resulted in a sample of 9578 individuals (66.8% females).
Supplementary Table 1 shows the self-report questionnaires used for
the current study.
2.2. Statistical analyses
We studied the association between lifetime ecstasy use and the
variables described in Supplementary Table 1 using Generalized Esti-
mating Equation (GEE) analysis. We added ‘family’ (indicating the fa-
mily a person belonged to) as repeated subject factor to account for
clustering within families. We conducted 4 separate sets of analyses
with respectively (a) demographic variables, health, satisfaction with
life and stress, (b) substance use variables, (c) personality variables, and
(d) symptoms of psychopathology as predictors, and lifetime ecstasy
use as outcome variable. First, univariate analyses were carried out.
Variables that were significantly associated (after Bonferroni correction
within group of variables) with lifetime ecstasy use were subsequently
included in multivariate analyses. Age, age2 and sex were included as
covariates in all analyses. To avoid multicollinearity, age was stan-
dardised (before squaring it). The odds ratio is used to present the effect
size of the individual variables. Participants with missing data were
listwise excluded from the analyses. A logistic regression analysis was
used to estimate the explained variance (with Nagelkerke pseudo R2).
To increase interpretation of comparability between associations of
continuous variables and ecstasy use, we conducted secondary analyses
in which we created z-scores of the continuous variables.
We determined the order of use for each substance compared to
ecstasy use, by subtracting age at first ecstasy use from age at first use of
another substance.
The associations between ecstasy use and the variables studied here
might reflect several underlying mechanisms. Co-occurrence could be
causal (where for example ecstasy use leads to use of other drugs or vice
versa), or could be due to overlapping underlying factors such as ge-
netic or environmental factors influencing both traits. The different
explanations for co-occurrence are not mutually exclusive and are dif-
ficult to distinguish. We have explored the nature of the association
with the co-twin control method (Stubbe, de Moor, Boomsma, & de
Geus, 2007; Lichtenstein et al., 2002). For the co-twin control method,
three groups were formed. Monozygotic (MZ) twin pairs discordant for
lifetime ecstasy use (N = 103), same-sex dizygotic (DZ) twin pairs
discordant for lifetime ecstasy use (N = 83) and 6206 unrelated twins
by randomly selecting one person from each family. In this last group,
8.1% had ever used ecstasy. Within each group, the strength of the
relationship between ecstasy use and the outcome variable is estimated.
For the MZ and DZ twin pairs we used a paired t-test (for continuous
variables) or McNemar test, a non-parametric test for 2 related samples
(for dichotomous variables). In order to calculate the matched-pairs
odds ratios we used the following formula: OR = b/c where b = the
number of pairs where the ecstasy using twin is affected with regard to
outcome measure (for example regular alcohol user, smoker) and the
non-using twin is not and c = the number of pairs in which the non-
using twin is affected and the using twin is not. The 95% confidence
interval for the OR is calculated with: EXP(−1.96*SQRT((1/b)+(1/c)))
and EXP(1.96*SQRT((1/b)+(1/c))) (IBM, 2019). A regression analysis
was used for the group of unrelated subjects. We only explored the
relationship for the variables that showed significant associations with
ecstasy use in the GEE analyses.
Three possible scenarios for comparing the magnitudes of these
relationships are shown in Fig. 1. Scenario A: if the influence is truly
causal (i.e. exposure to ecstasy directly contributes to liability to the
outcome) the ORs will be equivalent in all three groups: regardless of
one’s genetic and shared environmental status, exposure to ecstasy in-
creases the risk for the outcome. Scenario B: If the association is not
causal but is due to a third variable residing in shared family en-
vironment increasing both the risk to use ecstasy as well as liability for
the outcome variable, one would expect the OR in the individual
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sample to be larger and in the MZ and DZ discordant twin pairs
equivalently lower. Scenario C: if the association is not causal but due to
shared genetic influences that cause both ecstasy use and the outcome
measure, one would expect the OR in the unrelated sample to be larger.
In MZ discordant twin pairs the OR would be close to unity because the
ecstasy using and non-using members of an MZ pair discordant for
ecstasy use, would share their genetic predisposition for the outcome
variable. In DZ discordant twins, the OR would be intermediate because
the ecstasy using twin and the non-using co-twin share on average only
50% of their genetic predisposition to the outcome variable.
Power calculations for a matched pair design showed this sample
size is sufficient to detect an OR of 1.9 or higher (http://sampsize.
sourceforge.net/iface/s3.html, power 90%, 1:1 matched pair design)
(G*power version 3.1.9.2, test: means: difference between two depen-
dent means (matched pairs), alpha 0.05).
All statistical analyses were carried out using SPSS 24.0 and SPSS
25.0.
3. Results
3.1. Demographics, health, satisfaction with life and stress in relation to
ecstasy use
Of the 9578 individuals in our sample, 945 (9.9%) indicated to have
used ecstasy at least once in their life, of which 458 (51.3%) reported
ecstasy use in the past year. The average age at onset of ecstasy use was
21.1 years (SD = 4.3). The percentage males was higher in the group of
ecstasy users compared with non-users (Table 1). Ecstasy users were on
average younger, lived in urbanized areas more often and were more
often higher educated than non-users. Ecstasy users did not differ from
non-users with regard to self-reported health and feelings of loneliness.
However, ecstasy users did report more memory problems, less sa-
tisfaction with life, more stress at home and more financial stress
compared to non-users. Urbanicity and financial stress explained most
variance (R2 = 1.9% and 1.7% respectively) followed by memory
problems and sex (both R2 = 0.8%). These variables, together with
educational attainment remained significant in the multivariate ana-
lyses, while age, age2, satisfaction with life and stress at home did not
(Supplementary Table S2). The multivariate model explained 5.5% of
the variance in lifetime ecstasy use. The co-twin control method
(Supplementary Table 3) did not show clear patterns. ORs for all
variables were rather low, so for most variables the power was in-
sufficient to detect differences in our sample (see power calculation in
methods). If any pattern was detectable, the pattern for memory pro-
blems and financial stress was mostly in line with scenario B (en-
vironment).
3.2. Lifetime ecstasy use and use of other substances
Ecstasy users were significantly more likely to have used every other
substance compared to non-users (univariate analyses, Table 2). For
example, ecstasy users were more often current smokers (33.9%)
compared to non-users (11.6%) and had more often used cocaine (41%
versus 1% respectively). Ecstasy users also had significantly higher
mean scores on alcohol dependence as compared with non-users (9.30
versus 6.03). The explained variance was relatively high, ranging from
5.5–11.6% for smoking and alcohol, to 8.3–30.9% for illicit substances.
Multivariate analyses confirmed higher use of other substances in
lifetime ecstasy users compared to non-users (Supplementary Table 2)
although the ORs were somewhat lower. ORs were rather low for the
licit substances (1.69 for regular drinking, 1.67 for ever smoking, non-
significant for current smoking) indicating a limited risk to be a lifetime
ecstasy user when being a smoker or a regular drinker. The ORs were
higher for the illicit substances ranging from 4.44 for magic mushrooms
to 11.93 for amphetamine. These results indicate a high risk of poly-
drug use for a lifetime ecstasy user. All substance use variables together
(in combination with sex, age and age2) explained ~53% of the var-
iance in lifetime ecstasy use.
Licit substance use often preceded ecstasy use, with 83.5% of in-
dividuals started regular alcohol use and 73.2% regular smoking before
ecstasy (Supplementary Table 4). Also, use of cannabis usually pre-
ceded first ecstasy use (84% of the sample). The majority of participants
reported that ecstasy use preceded first use of other illicit substances
(GHB, cocaine, ketamine use, magic mushrooms). In addition, ecstasy
use either preceded (44.4%) or was initiated in the same year (48.0%)
as amphetamine use.
With regard to licit substance use, the results of the co-twin control
analyses for regular alcohol use and lifetime smoking were mostly in
line with Scenario B (environmental factors), with low to moderate ORs
(Table 3). For illicit substance use, the ORs were moderate to high and
patterns were also in line with Scenario B (family environment) espe-
cially for ketamine and GHB (and to some extent for cocaine), while the
pattern for cannabis was more in line with scenario C (genetic factors).
For amphetamines and mushrooms the OR for DZ twin pairs could not
be calculated because there were no twin pairs in which the non-using
twin had the outcome while the using twin did not. In general, there
was no evidence for a causal scenario where the ORs of the three groups
were equal (Scenario A), but it must be noted that, especially for the
illicit substances, the ORs in discordant MZ twins were high which in
itself is already an indication for a causal pathway on top of possible
other explanations.
3.3. Comparison of personality traits between ecstasy users and non-users
Lifetime ecstasy use was significantly associated with higher scores
on neuroticism, extraversion, openness to experience and all scales of
the Borderline personality scale and significantly lower scores on con-
scientiousness and agreeableness (Table 4). Self-harm and openness to
experience explained most of the variance in lifetime ecstasy use (3.8%
and 2.6% respectively).
Multivariate analyses confirmed that higher scores for extraversion,
openness to experience, negative relationships, self-harm and lower
scores for conscientiousness were related to a greater likelihood of
lifetime ecstasy use also when corrected for other personality scores
(Supplementary Table 2). Neuroticism, Agreeableness, Affect Instability
and Identity problems were no longer associated with lifetime ecstasy
Fig. 1. The co-twin control method. The figure depicts a possible result pattern
based on the Odds Ratio for the outcome variable given exposure to ecstasy in
an unrelated sample, in members of dizygotic (DZ) same-sex twin pairs dis-
cordant for ecstasy use and in members of monozygotic (MZ) twin pairs dis-
cordant for ecstasy. Scenario A suggests a causal link between ecstasy and
outcome. Scenario B suggests the relationship is due to the family environment
that predispose to both ecstasy use and the other variable. Scenario C suggests
the association is due to genetic factors that predispose to both ecstasy use and
the outcome variable. The figure is intended to be heuristic, as opposed to in-
volving precise point values corresponding with the exact heights of the lines in
the figure.
A. Vreeker, et al. Addictive Behaviors 108 (2020) 106421
3
use when correcting for other personality traits. In the multivariate
model, self-harm was the strongest predictor of lifetime ecstasy use. All
personality traits together (in combination with sex, age and age2)
explained 9.5% of the variance in lifetime ecstasy use.
Concerning the results of the co-twin control method
(Supplementary Table 3), no clear pattern was observed. The ORs were
in general low. The ORs in the unrelated sample were more often sig-
nificant, but this is due to the larger sample size.
3.4. Association between lifetime ecstasy use and symptoms of
psychopathology
Ecstasy users reported significantly more symptoms of anxiety, de-
pression, antisocial personality problems and ADH (attention deficit/
hyperactivity) problems than non-users (Table 5). Ecstasy users and
non-users did not differ on somatic problems and avoidant personality
problems. The strongest association with lifetime ecstasy use were
found with ADH problems (OR = 1.49, R2 = 3.0%) and Antisocial
personality (OR = 1.47, R2 = 2.5%). In the multivariate analyses these
two variables were the only variables that remained significant
(Supplementary Table 2). The multivariate model explained 4.4% of the
variance in lifetime ecstasy use.
The results of the co-twin control method (Supplementary Table 3)
showed highest ORs in the unrelated sample, followed by somewhat
lower ORs in DZ pairs and the lowest ORs in MZ pairs for Anxiety
problems, Antisocial personality problems and ADH problems. This
pattern is mostly in line with Scenario C (genetic factors), although
scenario B (environmental factors) cannot be ruled out. Scenario B was
more likely for depressive symptoms. However, power was limited in
these models.
3.5. Secondary analyses
Repeating univariate analyses using z-scores of continuous variables
as determinants and lifetime ecstasy use as outcome did not change the
results (data not shown), except for ASR somatic Problem scale;
whereas we did not find an association between ASR Somatic Problem
scale and lifetime ecstasy use in our models, we show a significant re-
lationship between the standardized scores and lifetime ecstasy use
(OR = 1.10, R2 < 0.01), suggesting that lifetime ecstasy use is related
to more somatic problems.
4. Discussion
In this large population-based sample aged 18–45 years, we found
that ecstasy users differed from non-ecstasy users on basically all
characteristics investigated (demographics, health, stress, substance
use, personality, psychopathology) with the strongest differences in
substance use. In our study, all substance use variables together with
sex and age explained ~ 53% of the variance in lifetime ecstasy use.
The association of lifetime ecstasy use was much stronger with illicit
drug use than with licit substance use (smoking, drinking). Licit sub-
stance use preceded ecstasy use in most cases. Most individuals re-
ported using ecstasy either before or in the same year as other illicit
substances. As to the interpretation of this observed trend, it is im-
portant to note the difference between sequence and causation: a
Table 1
Demographics, health, wellbeing and stress. Comparisons of lifetime ecstasy users and non-ecstasy users on demographics, health, wellbeing and stress using GEE,
with lifetime ecstasy use as the outcome variables (univariate analyses, with age, age2 and sex as covariates). N (number of participants for variable) can vary slightly
per variable. OR and 95% Confidence Interval show the effect size, the p-value indicates significance of the comparison and the R2 (=Nagelkerke Pseudo R2) gives
the explained variance for the individual variables.
N Lifetime ecstasy users Non-ecstasy Users OR [95%CI] p-value R2
Sex, male N (%) 9576 396 (41.9%) 2779 (32.2%) 1.51 [1.32–1.73] <0.001 0.8%
Age, mean (SD) 9578 27.34 (7.36) 28.79 (8.72) 0.98 [0.97–0.99] <0.001 0.5%
Urbanicity, high N (%) 9396 488 (52.1%) 3067 (36.3%) 1.91 [1.65–2.21] <0.001 1.9%
Educational level, high N (%) 9294 616 (67.4%) 5154 (61.5%) 1.28 [1.10–1.50] 0.001 0.3%
General health 9404 4.06 (0.70) 4.06 (0.69) 0.97 [0.88–1.07] 0.57 <0.1%
Memory problems, yes 9396 244 (26.4%) 1529 (18.0%) 1.54 [1.31–1.80] <0.001 0.8%
Loneliness, high 9186 460 (51.5%) 4073 (49.1%) 1.11 [0.97–1.28] 0.12 <0.1%
Satisfaction with life 9346 26.26 (5.46) 26.88 (5.20) 0.98 [0.97–0.99] <0.001 0.3%
Stress at home, moderate/high N (%) 9340 271 (29.6%) 2178 (25.9%) 1.27 [1.09 – 1.47] 0.002 0.1%
Stress at work, moderate/high N (%) 8768 335 (38.2%) 2721 (34.5%) 1.18 [1.03 – 1.36] 0.019 0.1%
Financial stress, moderate/high N (%) 9306 447 (49.0%) 2888 (34.4%) 1.79 [1.56 – 2.05] <0.001 1.7%
Note: P-value threshold after Bonferroni correction: 0.05/12 = 0.004. P-values below this threshold are indicated in bold. Family ID was included as repeated subject
factor to correct for family relatedness.
Table 2
Substance use. Comparisons of lifetime ecstasy users and non-ecstasy users on substance use using GEE, with lifetime ecstasy use as the outcome variables (univariate
analyses, with age, age2 and sex as covariates). N (number of participants for variable) can vary slightly per variable. OR and 95% Confidence Interval show the effect
size, the p-value indicates significance of the comparison and the R2 (=Nagelkerke Pseudo R2) gives the explained variance for the individual variables.
N Lifetime ecstasy users Non-users OR [95%CI] p-value R2
Alcohol dependence mean (SD) 4959 9.30 (5.07) 6.03 (3.92) 1.17 [1.15–1.19] <0.001 10.6%
Regular alcohol use N(%) 9313 668 (71.6%) 3751 (44.8%) 2.73 [2.36–3.17] <0.001 5.5%
Smoking cigarette, lifetime use N (%) 9560 837 (88.9%) 4470 (51.9%) 6.51 [5.31–7.97] <0.001 11.6%
Current smoking, N (%) 9523 318 (33.9%) 998 (11.6%) 3.43 [2.95–4.00] <0.001 6.1%
Cannabis, lifetime use N (%) 9565 818 (86.7%) 2257 (26.2%) 17.32 [14.21–21.11] <0.001 28.0%
Cocaine, lifetime use N (%) 9533 381 (41.0%) 87 (1.0%) 58.17 [45.59–74.22] <0.001 30.9%
Amphetamine, lifetime use N (%) 9527 300 (32.4%) 36 (0.4%) 84.49 [61.81–115.48] <0.001 26.5%
Ketamine, lifetime use N (%) 9518 92 (9.9%) 9 (0.1%) 65.96 [37.74–115.28] <0.001 8.3%
GHB, lifetime use N (%) 9504 121 (13.2%) 13 (0.2%) 70.42 [42.66–116.24] <0.001 10.8%
Mushrooms, lifetime use N (%) 9509 278 (30.2%) 146 (1.7%) 20.34 [16.23–25.49] <0.001 18.3%
Note: P-value threshold after Bonferroni correction: 0.05/11 = 0.005. P-values below this threshold are indicated in bold. Family ID was included as repeated subject
factor to correct for family relatedness.
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particular order of events does not always imply causation. Other me-
chanisms could also underlie the association between ecstasy use and
subsequent other illicit drug use (see below).
Within the first set of variables (demographics, health, wellbeing
and stress) urbanisation and financial stress showed the strongest as-
sociation with lifetime ecstasy use, followed by memory problems and
being male. Our finding that ecstasy users, compared to non-users,
more often lived in urban areas is in line with previous studies in the
Netherlands (van Laar et al., 2016), Australia (Lai et al., 2016) and the
United states (Gfroerer, Larson, & Colliver, 2007; Wu, Schlenger, &
Galvin, 2006). Gfroerer et al. stated that substance (ab)use in general is
not specifically an urban problem (Gfroerer et al., 2007), but for ecstasy
use this seems to be an important characteristic. This may be due to a
higher availability of ecstasy in urban areas, but also to a higher fre-
quency of recreational settings where ecstasy is used in urban areas,
such as clubs, nightlife events and dance festivals (Bryant et al., 2016;
Banta-Green et al., 2009; Lai et al., 2013; Warren, Smalley, & Barefoot,
2015). As far as we know, no other studies explored the relationship
between financial stress and ecstasy use. Ayllon and Ferreira-Batista
suggested that the consumption of certain drugs was positively related
to increasing unemployment rates (due to the Great Recession). The
mechanism for this phenomenon could be the ‘economic stress’ me-
chanism where people deal with uncertainty about future income by
taking substances as a form of self-medication (Ayllón & Ferreira-
Batista, 2017). This is in line with our results from the co-twin control
analyses, where scenario B was the most likely scenario: a non-causal
association between ecstasy and financial stress due to the (family)
environment. Unemployment or other stress about (family) income
could be such an environmental factor. Memory deficits are a well-
known side effect of (regular) ecstasy use (Laws & Kokkalis, 2007) al-
though with cross-sectional designs it cannot be determined whether
memory problems were caused by ecstasy use or already existed before
first-time use. We did not find evidence for a causal relationship be-
tween ecstasy use and memory problems with the co-twin control
study, but power was limited. If any pattern could be detected it was in
line with scenario B (overlapping environmental influences causing the
association between ecstasy use and memory problems).
Significantly higher prevalence rates were observed for ecstasy
users than their non-using co-twins for illicit substances (cannabis,
cocaine, amphetamine, ketamine, GHB and magic mushrooms), but not
for smoking and alcohol use. This suggests that either ecstasy use itself
is associated with use of other illicit substances (for example positive
experience with ecstasy leads to use of other drugs), or that an en-
vironmental factor not shared by the twin pairs (for example visiting
dance events or having substance using friends) influences the risk to
use of both ecstasy and other illicit substances. The results of the co-
twin control analyses showed that the association between ecstasy and
licit or illicit substance use is partly explained by a third factor, which
represents shared environmental factors and/or genetic factors. For
most substances, it was more likely that this third factor represented
shared environmental factors, while for cannabis a genetic factor was
more likely. However, for the illicit substances the ORs in discordant
MZ twin pairs were high, which means that the ecstasy using twin has a
significantly higher risk to use illicit substances compared to the non-
using co-twin. This is a strong indication for a causal relationship be-
tween ecstasy and other illicit drug use (since genetic and shared family
environmental factors are the same in MZ twin pairs). A causal effect
means that ecstasy use itself is increasing the risk to use of other drugs,
for example through positive experiences after ecstasy use. Based on
our results it is likely that there is a causal relationship on top of en-
vironmental (or genetic factors) that play a role in explaining the as-
sociation between ecstasy and other illicit drug use.
Table 4
Personality. Comparisons of lifetime ecstasy users and non-ecstasy users on the big five personality traits measured with the NEO, and on the subscales of Personality
Assessment Inventory – Borderline (PAI-BOR) using GEE, with lifetime ecstasy use as the outcome variables (univariate analyses, with age, age2 and sex as cov-
ariates). N (number of participants for variable) can vary slightly per variable. OR and 95% Confidence Interval show the effect size, the p-value indicates significance
of the comparison and the R2 (=Nagelkerke Pseudo R2) gives the explained variance for the individual variables.





NEO - Neuroticism 9396 19.91 (8.43) 18.98 (8.27) 1.02 [1.01 – 1.03] <0.001 0.2%
NEO - Extraversion 9396 31.54 (6.15) 30.15 (6.20) 1.03 [1.02 – 1.05] <0.001 0.9%
NEO - Conscientiousness 9396 31.87 (6.55) 33.86 (5.93) 0.95 [0.94 – 0.96] <0.001 2.0%
NEO - Openness to experience 9396 28.89 (6.71) 26.51 (6.21) 1.06 [1.04 – 1.07] <0.001 2.6%
NEO - Agreeableness 9396 31.16 (5.81) 32.31 (5.40) 0.97 [0.96 – 0.99] <0.001 0.8%
PAI BOR - Affect instability 9549 5.12 (3.32)1 4.40 (3.01)1 1.35 [1.23 – 1.47] <0.001 0.9%
PAI BOR – Identity Problems 9551 4.75 (3.21)1 4.15 (2.95)1 1.32 [1.20 – 1.44] <0.001 0.7%
PAI BOR – Negative relationships 9542 5.37 (3.25)1 4.52 (2.89)1 1.47 [1.33 – 1.62] <0.001 1.4%
PAI Bor - Self Harm 9546 3.28 (2.89)1 2.12 (2.15)1 1.67 [1.53 – 1.82] <0.001 3.8%
PAI Bor – Total Score 9552 18.51 (9.78)1 15.19 (8.43)1 1.43 [1.34 – 1.53] <0.001 2.6%
Note: P-value threshold after Bonferroni correction: 0.05/10 = 0.005. P-values below this threshold are indicated in bold. Family ID was included as repeated subject
factor to correct for family relatedness.1Mean and SD of the raw scores for the variable are presented.
Table 5
Psychopathology. Comparisons of lifetime ecstasy users and non-ecstasy users on the Adult Self Report using GEE, with lifetime ecstasy use as the outcome variables
(univariate analyses, with age, age2 and sex as covariates). N (number of participants for variable) can vary slightly per variable. OR and 95% Confidence Interval
show the effect size, the p-value indicates significance of the comparison and the R2 change (=Nagelkerke Pseudo R2) gives the explained variance for the individual
variables.
N Lifetime ecstasy users Non-users p-value OR [95% CI] R2
ASR Anxiety problems, M (SD) 9107 3.23 (2.85)1 3.02 (2.61)1 0.002 1.14 [1.05 – 1.23] 0.1%
ASR Depressive problems, M(SD) 9115 4.65 (4.42)1 4.03 (3.95)1 <0.001 1.20 [1.12 – 1.28] 0.4%
ASR Somatic problems, M(SD) 9080 2.03 (2.40)1 1.93 (2.22)1 0.11 1.07 [0.99 – 1.16] <0.1%
ASR Avoidant personality problems, M(SD) 9109 2.38 (2.47)1 2.55 (2.43)1 0.12 0.94 [0.87–1.02] 0.1%
ASR Antisocial personality problems, M(SD) 9117 3.30 (3.27)1 2.27 (2.21)1 <0.001 1.47 [1.34 – 1.62] 2.5%
ASR ADH problems, M(SD) 9115 6.17 (4.49)1 4.49 (3.70)1 <0.001 1.49 [1.38–1.61] 3.0%
P-value threshold after Bonferroni correction: 0.05/6 = 0.008. P-values below this threshold are indicated in bold. Family ID was included as repeated subject factor
to correct for family relatedness. 1Mean and SD of the raw scores for the variable are presented.
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We showed that ecstasy users have different personality scores on
all subscales compared to non-users. This is in line with previous,
smaller studies that reported associations in the same directions for
comparable traits (Bobes et al., 2002; Butler & Montgomery, 2004;
Singer et al., 2004; ter Bogt et al., 2006). The power in our co-twin
control analyses was not sufficient for most personality scores to further
clarify the nature of the relationship.
In the present study, ecstasy users showed significantly less fa-
vourable scores on most psychopathology scores compared to non-
users. Previous, relatively small studies showed contrasting results,
with some studies suggesting ecstasy as causal factor for psycho-
pathology, like depression and anxiety (Taurah et al., 2014), while
others excluded this causality (Durdle, Lundahl, Johanson, & Tancer,
2008; Falck, Wang, & Carlson, 2008). A longitudinal study (N = 1580)
suggested that childhood depression and anxiety could predict ecstasy
use in adolescence or young adulthood (Huizink et al., 2006), but this
association could still be due to a third factor (genetic or environ-
mental). Based on our co-twin control study (although power was
limited), we did not find evidence for a causal pathway. For Anxiety
problems, Antisocial personality problems and ADH problems Scenario
C (underlying genetic factors) was more likely, although Scenario B
(shared environmental factors) could not be ruled out. Scenario B was
more likely for depressive symptoms.
Indeed, from previous twin studies we know that genetic factors
play a role in personality and psychopathology (Bassir Nia et al., 2018;
Briley & Tucker-Drob, 2014) and we recently showed for the first time
that genetic factors (in addition to environmental factors) play a role in
ecstasy use, with a heritability estimate of 74% (Verweij et al., 2017).
Future research with a larger number of twin pairs should investigate
whether and which specific genetic or environmental factors for ecstasy
use and psychopathology overlap in order to explain their co-morbidity.
The current study has several limitations. Lifetime ecstasy use (yes/
no) was used without distinguishing experimenters from regular users.
It is possible that characteristics such as psychopathology, but also
other drug use, differ between incidental and regular ecstasy users.
Another issue that needs consideration is polydrug use: most ecstasy
users also use other substances and the use of other substances is also
associated with psychopathology and personality traits. Also, we did
not have longitudinal data on ecstasy use; it is possible that current non-
users will start using ecstasy in a later phase of their life. Furthermore,
we used self-report data which may have led to underreporting of un-
desirable behaviour such as substance use. However, bias is likely to be
limited in this sample (Vink et al., 2004). Lastly, the power of the co-
twin control study to detect significant differences was not sufficient for
several variables (when OR < 1.9 (i.e. for demographics, health, al-
cohol dependence, psychopathology and personality), see
Supplementary Table 3), and no firm conclusions can be drawn for
these variables with regard to the underlying mechanism explaining the
nature of the associations.
In conclusion, we aimed to provide a broad overview of char-
acteristics of ecstasy users compared to non-users in a large, population-
based sample. Our data clearly demonstrate that ecstasy users in a
population-based sample differed from non-ecstasy users on a wide
range of variables including substance use, urbanicity, financial stress,
personality and psychopathology. Use of licit substances often preceded
first use of ecstasy, and first ecstasy use often preceded first use of other
illicit substances. These findings, combined with those from the co-twin
control analyses, suggest ecstasy is highly associated with the use of
other illicit substances, often as starting substance of choice. The as-
sociation may be due to several factors, most likely environmental
variables (e.g. accessibility to the substance or recreational setting
where the drug is used), but genetic factors cannot be ruled out. In
addition, causal effects play a role in explaining the relationship be-
tween ecstasy use and other illicit substance use. No evidence was
found for a direct causal relationship underlying the link between ec-
stasy use and personality, psychopathology or demographics and well-
being in the current study, but power was limited. Last, the fact that
ecstasy use is related to multiple factors with modest to large effects
underscores the need for prevention and intervention strategies to focus
on a broad range of factors.
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